Jillion's projects are supported by the National Institutes of Health (NIH).
Nobel-Inspired Drug Development: Pioneering CNS Therapies of Tomorrow. With over two decades of experience in a Nobel Prize-winning lab, Jillion's founder brings unparalleled expertise in brain signaling and disease mechanisms.
This profound knowledge has been key to shaping our innovative bottom-up approach.
Jillion’s efforts are accelerating pre-clinical drug discovery by rapidly generating a wide array of new drug leads for innovative CNS treatments.
.png)
High-Power Screening with DNA-Encoded Libraries (DELs). Jillion's team coined the term “HPS” in the review "High-power screening (HPS) empowered by DNA-encoded libraries" published in Trends in Pharmacological Sciences (2022 Jan; 43(1):4-15).
.png)
Seamless Integration of Chemistry, Neuroscience, HPS Drug Screening and A.I. Proprietary and licensed methods tightly couple chemistry with neuroscience and HPS screening, while A.I. and machine learning will drive hit and lead optimization.
By targeting novel and impactful CNS therapeutic areas and maintaining control over key drug discovery stages, Jillion is poised to revolutionize the field of medicine.
.png)